MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
13 Julho 2023 - 9:05AM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics and to
support innovative cell-based research, today announced that it
will release financial results for the second quarter 2023 after
the U.S. market close on Wednesday, August 9th, 2023. Company
management will host a conference call to discuss financial results
at 4:30 p.m. Eastern Time.
Earnings Conference Call DetailsInvestors
interested in listening to the conference call are required to
register online. It is recommended to register at least a day in
advance. A live and archived webcast of the event will be available
on the “Events” section of the MaxCyte website at
https://investors.maxcyte.com/.
About MaxCyteAt MaxCyte, we
pursue cell engineering excellence to maximize the potential of
cells to improve patients’ lives. We have spent more than 20 years
honing our expertise by building best-in-class platforms,
perfecting the art of the transfection workflow, and venturing
beyond today’s processes to innovate tomorrow’s solutions. Our
ExPERT™ platform, which is based on our Flow Electroporation®
technology, has been designed to support the rapidly expanding cell
therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development
through commercialization of next-generation, cell-based medicines.
The ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx ™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn.
MaxCyte Contacts:
US IR AdviserGilmartin
GroupDavid Deuchler, CFA+1 415-937-5400ir@maxcyte.com
Nominated Adviser and Joint Corporate
BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserConsilium Strategic
CommunicationsMary-Jane Elliott / Chris Welsh+44 (0)203
709 5700maxcyte@consilium-comms.com
MaxCyte (NASDAQ:MXCT)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
MaxCyte (NASDAQ:MXCT)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024